contentSlug

type

ContentSlug_ContentQuery

slug

ContentPageContentQuery

content

trendingContent

query ContentSlug_ContentQuery(
  $contentSlug: String!
  $type: [ContentType!]
) {
  ...ContentPageContentQuery_13QmVO
}

fragment CompanyDetails_Content on Content {
  __isContent: __typename
  companies {
    name
    description
    pageUrl
    id
  }
}

fragment CompanyTagList on Company {
  pageUrl
  name
  viewerIsFollowing
}

fragment ContentBasicInfo on Content {
  __isContent: __typename
  id
  type
  title
  lang
  companies {
    ...CompanyTagList
    id
  }
  ...PublishingDetails
  ...Reactions
}

fragment ContentMetadata on Content {
  __isContent: __typename
  type
  title
  lang
  pageUrl
  alternatePageUrls: translations {
    __typename
    pageUrl
    lang
  }
  imgUrl
  description
  ... on Video {
    liveTime
    videoUrl
  }
  ... on Webcast {
    liveTime
    videoUrl
  }
}

fragment ContentPageContentQuery_13QmVO on Query {
  content(slug: $contentSlug, type: $type) {
    __typename
    id
    type
    title
    isPremium
    lang
    htmlBody
    companies {
      forum {
        latestPosts {
          ...ForumPosts
        }
      }
      name
      defaultInstrument {
        isin
        id
        marketOpen
        marketClose
        marketplace {
          region
        }
        returns {
          total
        }
      }
      id
    }
    createdAt
    ... on Video {
      liveTime
    }
    ... on Webcast {
      liveTime
    }
    slug
    ... on CompanyReport {
      reportUrl
    }
    ... on ThirdPartyCompanyReport {
      reportUrl
    }
    ... on StockExchangeRelease {
      reportUrl
    }
    ...ContentBasicInfo
    ...ContentMetadata
    ...PriceAndRecommendation_Content
    ...CompanyDetails_Content
    ...ReportLink_Content
    ...KeyFigures_Content
  }
  ...TrendingContent_1jQ2Cn
}

fragment ForumPosts on ForumPost {
  text
  likesCount
  url
  author
  postedAt
  authorImgUrl
}

fragment KeyFigures_Content on Content {
  __isContent: __typename
  companies {
    defaultInstrument {
      estimateData {
        modelType
        reportingCurrency
      }
      snapshot {
        transaction {
          date
          actualized {
            year
            quarter
            revenue
            revenueGrowth
            ebitAdjusted
            ebitReported
            ebitda
            enterpriseValue
            epsAdjusted
            dividend
            dividendYield
            sharePrice
          }
          estimates {
            year
            quarter
            revenue
            revenueGrowth
            ebitAdjusted
            ebitReported
            ebitda
            enterpriseValue
            epsAdjusted
            dividend
            dividendYield
            sharePrice
          }
        }
      }
      id
    }
    id
  }
}

fragment PriceAndRecommendation_Content on Content {
  __isContent: __typename
  createdAt
  companies {
    id
    name
    pageUrl
    viewerIsFollowing
    defaultInstrument {
      snapshot {
        priceData {
          date
          lastPrice
          tradeCurrency
        }
        transaction {
          date
          recommendation
          targetPrice
        }
        prevTransaction {
          recommendation
        }
      }
      id
    }
  }
}

fragment PublishingDetails on Content {
  __isContent: __typename
  createdAt
  publishers {
    name
    imgUrl
  }
  authors {
    __typename
    id
    name
    slug
    imgUrl
    jobTitle
  }
  ... on Video {
    liveTime
  }
  ... on Webcast {
    liveTime
  }
}

fragment Reactions on Content {
  __isContent: __typename
  id
  reactionGroups {
    reactionType
    reactionsCount
    viewerReacted
  }
}

fragment ReportLink_Content on Content {
  __isContent: __typename
  type
  isPremium
  ... on CompanyReport {
    reportUrl
  }
  ... on ThirdPartyCompanyReport {
    reportUrl
  }
  ... on StockExchangeRelease {
    reportUrl
  }
}

fragment TrendingContent_1jQ2Cn on Query {
  trendingContent(type: ARTICLE) {
    __typename
    id
    title
    lang
    pageUrl
    createdAt
    type
    imgUrl
    companies {
      squareLogoUrl
      name
      id
    }
    authors {
      __typename
      imgUrl
      id
    }
    publishers {
      imgUrl
    }
  }
}


biohit-oyjs-financial-reporting-and-annual-general-meeting-in-2023

__typename

title

isPremium

lang

htmlBody

companies

createdAt

publishers

authors

reactionGroups

pageUrl

translations

imgUrl

description

Biohit is a medical technology company. The company develops and manufactures laboratory equipment, supplies, and diagnostic analysis systems adapted for research, care, and industrial laboratories. In addition to the main activities, technical support, maintenance, and training services are offered within the mentioned work area. The largest presence is in the Nordic market. The company is headquartered in Helsinki.

Biohit

Publishing on November 30, 2022 at 2:00 pm local time (EEST)Biohit Oyj will release its financial statements for 2022 on Wednesday February 15th, 2023, at 9:30 am.The Annual report, which contains...

Publishing on November 30, 2022 at 2:00 pm local time (EEST)Biohit Oyj will release its financial statements for 2022 on Wednesday February 15th, 2023, at 9:30 am.The Annual report, which contains the Financial Statement for 2022 and the Report of the Board of Directors, will be published on Wednesday March 22nd, 2023, at 9:30 am.Biohit Oyj's Annual General Meeting has been planned for Wednesday 14th of June 2023 at 2:00 pm. The Board of Directors will call the General meeting at a later date.Half year financial report for period January-June (H1) 2023 will be published on Wednesday 9th of August, 2023, at 9:30 am.The published economic reports and other stock exchange releases are available on Biohit's website atwww.biohithealthcare.com/investors&nbsp;(<a href="https://eur04.safelinks.protection.outlook.com/?url=http%3A%2F%2Fwww.biohithealthcare.com%2Finvestors&amp;data=04%7C01%7CSanna.Kurlin%40biohit.fi%7Ce79379bd970246069f0608d9d50d0c93%7C4da67d2fc92245f9b72584364b1decf5%7C0%7C0%7C637775074284926203%7CUnknown%7CTWFpbGZsb3d8eyJWIjoiMC4wLjAwMDAiLCJQIjoiV2luMzIiLCJBTiI6Ik1haWwiLCJXVCI6Mn0%3D%7C3000&amp;sdata=7uDFWWvj4lup7uSXXVeo7EDJ4c71OBR%2FIVMnjPOA%2BWg%3D&amp;reserved=0">https://eur04.safelinks.protection.outlook.com/?url=http%3A%2F%2Fwww.biohithealthcare.com%2Finvestors&amp;data=04%7C01%7CSanna.Kurlin%40biohit.fi%7Ce79379bd970246069f0608d9d50d0c93%7C4da67d2fc92245f9b72584364b1decf5%7C0%7C0%7C637775074284926203%7CUnknown%7CTWFpbGZsb3d8eyJWIjoiMC4wLjAwMDAiLCJQIjoiV2luMzIiLCJBTiI6Ik1haWwiLCJXVCI6Mn0%3D%7C3000&amp;sdata=7uDFWWvj4lup7uSXXVeo7EDJ4c71OBR%2FIVMnjPOA%2BWg%3D&amp;reserved=0</a>). The website also contains an online form for ordering electronic copies, which will be e-mailed to you, available at <a href="http://www.biohithealthcare.com/investors/stock-exchange-releases/order-releases-to-your-email%C2%A0(https://eur04.safelinks.protection.outlook.com/?url=http%3A%2F%2Fwww.biohithealthcare.com%2Finvestors%2Fstock-exchange-releases%2Forder-releases-to-your-email&amp;data=04%7C01%7CSanna.Kurlin%40biohit.fi%7Ce79379bd970246069f0608d9d50d0c93%7C4da67d2fc92245f9b72584364b1decf5%7C0%7C0%7C637775074284926203%7CUnknown%7CTWFpbGZsb3d8eyJWIjoiMC4wLjAwMDAiLCJQIjoiV2luMzIiLCJBTiI6Ik1haWwiLCJXVCI6Mn0%3D%7C3000&amp;sdata=T9Onb0KniS%2Flhg6rgsFua6748gimIaDtPmi%2BeUkknHU%3D&amp;reserved=0)">http://www.biohithealthcare.com/investors/stock-exchange-releases/order-releases-to-your-email&nbsp;(https://eur04.safelinks.protection.outlook.com/?url=http%3A%2F%2Fwww.biohithealthcare.com%2Finvestors%2Fstock-exchange-releases%2Forder-releases-to-your-email&amp;data=04%7C01%7CSanna.Kurlin%40biohit.fi%7Ce79379bd970246069f0608d9d50d0c93%7C4da67d2fc92245f9b72584364b1decf5%7C0%7C0%7C637775074284926203%7CUnknown%7CTWFpbGZsb3d8eyJWIjoiMC4wLjAwMDAiLCJQIjoiV2luMzIiLCJBTiI6Ik1haWwiLCJXVCI6Mn0%3D%7C3000&amp;sdata=T9Onb0KniS%2Flhg6rgsFua6748gimIaDtPmi%2BeUkknHU%3D&amp;reserved=0)</a>.Additional information: Jussi Hahtela, CEO, Biohit Oyj, tel. +358 50383 5948investor.relations@biohit.fi www.biohithealthcare.comBiohit in briefBiohit Oyj is a globally operating Finnish biotechnology company. Biohit mission is "Innovating for Health" - we produce innovative products and services to promote research and early diagnosis. Biohit is headquartered in Helsinki, Finland, and has subsidiaries in Italy and the UK. Biohit Series B share (BIOBV) is quoted on Nasdaq Helsinki in the Small cap/Healthcare group.www.biohithealthcare.com&nbsp;(<a href="https://www.globenewswire.com/Tracker?data=ciyb_iZ945H2z3sK3a9i7Zs03Nkj9jr5Brw7kC1tsoUye5PVgko06PC57Z9BVVT2pXUgp6sn-tswLd2MUgQOQc8UNXD2BkNm3L02XzRJ7XfJCPaPUqGS1mpI0NZinK5T">https://www.globenewswire.com/Tracker?data=ciyb_iZ945H2z3sK3a9i7Zs03Nkj9jr5Brw7kC1tsoUye5PVgko06PC57Z9BVVT2pXUgp6sn-tswLd2MUgQOQc8UNXD2BkNm3L02XzRJ7XfJCPaPUqGS1mpI0NZinK5T</a>)